Identification and Validation of Oncologic miRNA Biomarkers for Luminal A-like Breast Cancer

Introduction Breast cancer is a common disease with distinct tumor subtypes phenotypically characterized by ER and HER2/neu receptor status. MiRNAs play regulatory roles in tumor initiation and progression, and altered miRNA expression has been demonstrated in a variety of cancer states presenting the potential for exploitation as cancer biomarkers. Blood provides an excellent medium for biomarker discovery. This study investigated systemic miRNAs differentially expressed in Luminal A-like (ER+PR+HER2/neu-) breast cancer and their effectiveness as oncologic biomarkers in the clinical setting. Methods Blood samples were prospectively collected from patients with Luminal A-like breast cancer (n = 54) and controls (n = 56). RNA was extracted, reverse transcribed and subjected to microarray analysis (n = 10 Luminal A-like; n = 10 Control). Differentially expressed miRNAs were identified by artificial neural network (ANN) data-mining algorithms. Expression of specific miRNAs was validated by RQ-PCR (n = 44 Luminal A; n = 46 Control) and potential relationships between circulating miRNA levels and clinicopathological features of breast cancer were investigated. Results Microarray analysis identified 76 differentially expressed miRNAs. ANN revealed 10 miRNAs for further analysis (miR-19b, miR-29a, miR-93, miR-181a, miR-182, miR-223, miR-301a, miR-423-5p, miR-486-5 and miR-652). The biomarker potential of 4 miRNAs (miR-29a, miR-181a, miR-223 and miR-652) was confirmed by RQ-PCR, with significantly reduced expression in blood of women with Luminal A-like breast tumors compared to healthy controls (p = 0.001, 0.004, 0.009 and 0.004 respectively). Binary logistic regression confirmed that combination of 3 of these miRNAs (miR-29a, miR-181a and miR-652) could reliably differentiate between cancers and controls with an AUC of 0.80. Conclusion This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection.

[1]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[2]  B. Burwinkel,et al.  Characterization of extracellular circulating microRNA , 2011, Nucleic acids research.

[3]  Brigitte Rack,et al.  Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer , 2010, Breast Cancer Research.

[4]  Yue Yu,et al.  Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. , 2010, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[5]  Michael J Kerin,et al.  Circulating microRNAs as Novel Minimally Invasive Biomarkers for Breast Cancer , 2010, Annals of surgery.

[6]  S. Eccles,et al.  Metastasis: recent discoveries and novel treatment strategies , 2007, The Lancet.

[7]  J. O'fallon,et al.  The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer , 1986, Cancer.

[8]  Tai-Yue Kuo,et al.  Computational Analysis of mRNA Expression Profiles Identifies MicroRNA-29a/c as Predictor of Colorectal Cancer Early Recurrence , 2012, PloS one.

[9]  Wei Li,et al.  Plasma microRNAs, miR-223, miR-21 and miR-218, as Novel Potential Biomarkers for Gastric Cancer Detection , 2012, PloS one.

[10]  K. Horgan,et al.  Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours , 2012, Cellular Oncology.

[11]  E. Kroh,et al.  Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma , 2011, Proceedings of the National Academy of Sciences.

[12]  Massimo Negrini,et al.  Micromarkers: miRNAs in cancer diagnosis and prognosis , 2010, Expert review of molecular diagnostics.

[13]  G. Ball,et al.  A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks , 2010, Breast Cancer Research and Treatment.

[14]  Christophe Lemetre,et al.  MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer , 2009, Breast Cancer Research.

[15]  Hua Zhao,et al.  A Pilot Study of Circulating miRNAs as Potential Biomarkers of Early Stage Breast Cancer , 2010, PloS one.

[16]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[17]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[18]  A. Keller,et al.  Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening , 2010, British Journal of Cancer.

[19]  K. Mimori,et al.  microRNA-181a is associated with poor prognosis of colorectal cancer. , 2012, Oncology reports.

[20]  Satoru Takahashi,et al.  miR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer. , 2013, Endocrine-related cancer.

[21]  R. Bast,et al.  The CA 125 tumour-associated antigen: a review of the literature. , 1989, Human reproduction.

[22]  F. Su,et al.  Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells , 2011, Molecular Cancer.

[23]  A. McDermott,et al.  Relationship between Circulating and Tissue microRNAs in a Murine Model of Breast Cancer , 2012, PloS one.

[24]  Leonard D. Goldstein,et al.  MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype , 2007, Genome Biology.

[25]  N. Aoki,et al.  Adipocyte-derived microvesicles contain RNA that is transported into macrophages and might be secreted into blood circulation. , 2010, Biochemical and biophysical research communications.

[26]  Lianbo Yu,et al.  Detection of microRNA Expression in Human Peripheral Blood Microvesicles , 2008, PloS one.

[27]  Zuhong Lu,et al.  Analysis of serum genome-wide microRNAs for breast cancer detection. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[28]  X. Chen,et al.  Genetic polymorphism at miR-181a binding site contributes to gastric cancer susceptibility. , 2012, Carcinogenesis.

[29]  Lijuan Guo,et al.  Decreased serum miR-181a is a potential new tool for breast cancer screening. , 2012, International journal of molecular medicine.

[30]  Michael J Kerin,et al.  Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. , 2010, The oncologist.

[31]  N. Miller,et al.  Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer , 2008, BMC Molecular Biology.

[32]  N. Park,et al.  miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras. , 2011, Biochemical and biophysical research communications.

[33]  V. Treviño,et al.  Differential expression of miR‐21, miR‐125b and miR‐191 in breast cancer tissue , 2013, Asia-Pacific journal of clinical oncology.

[34]  J. Lötvall,et al.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.

[35]  P. Kuo,et al.  Micro-RNA-181a regulates osteopontin-dependent metastatic function in hepatocellular cancer cell lines. , 2010, Surgery.

[36]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[37]  T. D. de Gruijl,et al.  Functional delivery of viral miRNAs via exosomes , 2010, Proceedings of the National Academy of Sciences.

[38]  L. Fan,et al.  Polymorphism rs4919510:C>G in Mature Sequence of Human MicroRNA-608 Contributes to the Risk of HER2-Positive Breast Cancer but Not Other Subtypes , 2012, PloS one.

[39]  J. Crowley,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.

[40]  Qiong Shao,et al.  MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. , 2008, RNA.

[41]  A. Luo,et al.  MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1 , 2013, Oncogene.

[42]  Z. Tulassay,et al.  Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer , 2008, BMC Cancer.

[43]  Yanhong Zhou,et al.  Circulating miR-17, miR-20a, miR-29c, and miR-223 Combined as Non-Invasive Biomarkers in Nasopharyngeal Carcinoma , 2012, PloS one.

[44]  Christophe Lemetre,et al.  MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease , 2011, International Journal of Colorectal Disease.

[45]  Fátima Sánchez-Cabo,et al.  Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells , 2011, Nature communications.

[46]  R. Aharonov,et al.  Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer. , 2012, International journal of oncology.